Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

Christine R Jenkins, Paul W Jones, Peter M A Calverley, Bartolome Celli, Julie A Anderson, Gary T Ferguson, Julie C Yates, Lisa R Willits, Jörgen Vestbo, Christine R Jenkins, Paul W Jones, Peter M A Calverley, Bartolome Celli, Julie A Anderson, Gary T Ferguson, Julie C Yates, Lisa R Willits, Jörgen Vestbo

Abstract

Background: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. However, there are only limited data about the influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder disease.

Methods: TORCH was a 3-year, double-blind, placebo-controlled trial of 6112 patients with moderate/severe COPD with pre-bronchodilator FEV1 < 60% predicted (mean age 65 years, 76% male, mean 44% predicted FEV1, 43% current smokers). To understand the relative efficacy of SFC and its components by GOLD stages, we conducted a post-hoc analysis of the TORCH dataset using baseline post-bronchodilator FEV1 to segment patients into three groups: moderate COPD (GOLD stage II and above: >or= 50%; n = 2156), severe COPD (GOLD stage III: 30% to < 50%; n = 3019) and very severe COPD (GOLD stage IV: < 30%; n = 937).

Results: Compared with placebo, SFC improved post-bronchodilator FEV1: 101 ml (95% confidence interval [CI]: 71, 132) in GOLD stage II, 82 ml (95% CI: 60, 104) in GOLD stage III and 96 ml (95% CI: 54, 138) in GOLD stage IV patients, and reduced the rate of exacerbations: 31% (95% CI: 19, 40) in GOLD stage II, 26% (95% CI: 17, 34) in GOLD stage III and 14% (95% CI: -4, 29) in GOLD stage IV. SFC improved health status to a greater extent than other treatments regardless of baseline GOLD stage. Similarly, SFC reduced the risk of death by 33% (hazard ratio [HR] 0.67; 95% CI: 0.45, 0.98) for GOLD stage II, 5% (HR 0.95; 95% CI: 0.73, 1.24) for GOLD stage III, and 30% (HR 0.70; 95% CI: 0.47, 1.05) for GOLD stage IV. The rates of adverse events were similar across treatment arms and increased with disease severity. Overall, there was a higher incidence of pneumonia in the fluticasone propionate and SFC arms, compared with other treatments in all GOLD stages.

Conclusion: In the TORCH study, SFC reduced moderate-to-severe exacerbations and improved health status and FEV1 across GOLD stages. Treatment with SFC may be associated with reduced mortality compared with placebo in patients with GOLD stage II disease. The effects were similar to those reported for the study as a whole. Thus, SFC is an effective treatment option for patients with GOLD stage II COPD.

Trial registration: Clinicaltrial.gov registration NCT00268216; Study number: SCO30003.

Figures

Figure 1
Figure 1
Rate of withdrawal of patients over the 3-years duration of the study by baseline post-bronchodilator FEV1 % predicted.
Figure 2
Figure 2
All-cause mortality by baseline post-bronchodilator FEV1 % predicted.
Figure 3
Figure 3
Exacerbation rate by baseline post-bronchodilator FEV1 % predicted.
Figure 4
Figure 4
Adjusted mean FEV1 over 3 years by baseline post-bronchodilator FEV1 % predicted.
Figure 5
Figure 5
Rate of decline in FEV1 by baseline post-bronchodilator FEV1 % predicted.
Figure 6
Figure 6
Improvement (reduction) in SGRQ vs placebo by baseline post-bronchodilator FEV1 % predicted.
Figure 7
Figure 7
Probability* of pneumonia by 156 weeks by baseline post-bronchodilator FEV1 % predicted. *Kaplan-Meier probability.

References

    1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
    1. Calverley PM, Anderson JA, Celli B, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi: 10.1056/NEJMoa063070.
    1. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi: 10.1164/rccm.200707-973OC.
    1. Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007;132(6):1756–1763. doi: 10.1378/chest.06-3009.
    1. Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbo J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):209–218.
    1. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone propionate in the treatment of COPD: a randomised controlled trial. Lancet. 2003;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2.
    1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919. doi: 10.1183/09031936.03.00027003.
    1. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834–843. doi: 10.1378/chest.124.3.834.
    1. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81. doi: 10.1183/09031936.03.00031402.
    1. Decramer M, Celli B, Burkhart D, Kesten S, Mehra S, Liu D, Tashkin D. The Effect of Tiotropium on COPD GOLD stage II during the four-year UPLIFT trial [abstract] Am J Respir Crit Care Med. 2009;179:A2466.
    1. Vestbo J, TORCH Study Group The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J. 2004;24(2):206–210. doi: 10.1183/09031936.04.00120603.
    1. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–664. doi: 10.1136/thorax.58.8.659.
    1. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338. doi: 10.1164/rccm.200712-1869OC.
    1. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084–1091. doi: 10.1164/rccm.2112055.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever